

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/243299 A1

(43) International Publication Date
24 November 2022 (24.11.2022)

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
A61K 31/712 (2006.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/EP2022/063300

(22) International Filing Date:

17 May 2022 (17.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/201,887 17 May 2021 (17.05.2021) US

(71) Applicant: **NOGRA PHARMA LIMITED** [IE/IE]; 33 Sir John Rogerson's Quay, Dublin, 2 (IE).

(72) Inventors: **VITI, Francesca**; 33 Sir John Rogerson's Quay, Dublin, 2 (IE). **MCNULTY, Marie**; 33 Sir John Rogerson's Quay, Dublin, 2 (IE). **BELLINVIA, Salvatore**; 33 Sir John Rogerson's Quay, Dublin, 2 (IE).

(74) Agent: **HGF LTD**; 1 City Walk, Leeds Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: IL-34 ANTISENSE AGENTS AND METHODS OF USING SAME




FIG. 1

(57) Abstract: Disclosed herein polynucleotides complementary to IL-34, including IL-34 antisense oligonucleotides and IL-34 siRNAs, and methods for treating inflammatory diseases, such as an inflammatory bowel disease, and/or fibrosis, associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing a polynucleotide complementary to IL-34, for example, an IL-34 antisense oligonucleotide or an IL-34 siRNA, useful for treating inflammatory diseases and/or fibrosis and manufacture of medicaments containing a disclosed polynucleotide to be used in treating inflammatory diseases and/or fibrosis.



WO 2022/243299 A1